Back to Search
Start Over
United States : Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme
- Source :
- Mena Report. April 4, 2017
- Publication Year :
- 2017
-
Abstract
- Bristol-Myers Squibb Company today announced that CheckMate -143, a randomized Phase 3 clinical trial evaluating the efficacy and safety of Opdivo in patients with first recurrence of glioblastoma multiforme (GBM), [...]
Details
- Language :
- English
- ISSN :
- 22190112
- Database :
- Gale General OneFile
- Journal :
- Mena Report
- Publication Type :
- News
- Accession number :
- edsgcl.489744768